Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQEJVU)

Drug Name
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Drug Info
Synonyms
1-((2-Chlorophenyl)diphenylmethyl)-1H-pyrazole; TRAM-34; 289905-88-0; Tram 34; 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole; AC1LCVHZ; CHEMBL498270; CHEBI:34990; 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole; 1-(2-Chlorophenyl)diphenyl)methyl]-1H-pyrazole; SureCN41130; TRAM34; SCHEMBL41130; GTPL2336; KS-00000OJW; CTK0J1643; DTXSID70349650; MolPort-003-850-592; EX-A2316; BCP01324; ZINC3975392; BDBM50279107; ANW-72309; s1160; MFCD09842562; AKOS005146304; CS-1921; ACN-048484; MP-2041; API0000868; DS-2617; NCGC00165909-03; NCGC00165909-02
Indication
Disease Entry ICD 11 Status REF
Conjunctival fibrosis 9A61.3 Investigative [1]
Cross-matching ID
PubChem CID
656734
ChEBI ID
CHEMBL498270
CAS Number
CAS 289905-88-0
TTD Drug ID
DMQEJVU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Calcium-activated potassium channel (KCN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Chlorzoxazone DMCYVDT Acute pain MG31 Approved [4]
Charybdotoxin DMKN345 Scorpion envenoming syndrome 8D43 Approved [5]
ICA-17043 DMRFY7I Alzheimer disease 8A20 Phase 2 [6]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [2]
4-fluorophenyl-2,2-diphenylacetamide DMI03KV Discovery agent N.A. Investigative [6]
N-methyl-2,2,2-triphenylacetamide DMQGRMO Discovery agent N.A. Investigative [6]
TRIPHENYLMETHANAMINE DM3CQIZ Discovery agent N.A. Investigative [6]
N,N-dimethyl-2,2,2-triphenylacetamide DM9XZJN Discovery agent N.A. Investigative [6]
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide DMFV76H Discovery agent N.A. Investigative [6]
2,2,2-tris-(3-fluorophenyl)-acetamide DMJXAF7 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Calcium-activated potassium channel KCa3.1 (KCNN4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ICA-17043 DMRFY7I Alzheimer disease 8A20 Phase 2 [7]
ASP0819 DM6HJ3V Fibromyalgia MG30.01 Phase 2 [8]
EBIO DMPKI0N Discovery agent N.A. Investigative [9]
DC-EBIO DM2T5OV Discovery agent N.A. Investigative [10]
SKA-121 DMBL7YN Discovery agent N.A. Investigative [11]
PMID15603962Crac-16 DMN5LZQ Discovery agent N.A. Investigative [12]
SKA-31 DMX34F1 Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium-activated potassium channel (KCN) TTMNI76 NOUNIPROTAC Inhibitor [2]
Calcium-activated potassium channel KCa3.1 (KCNN4) TT7M9I6 KCNN4_HUMAN Blocker (channel blocker) [3]

References

1 Blockade of KCa3.1: A novel target to treat TGF-1 induced conjunctival fibrosis.Exp Eye Res. 2018 Feb;167:140-144.
2 Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
3 Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
4 Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
5 Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
6 Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
7 Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9.
8 Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369.
9 Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
10 Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2001 Feb;296(2):600-11.
11 New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep;86(3):342-57.
12 IKCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg Med Chem Lett. 2005 Jan 17;15(2):401-4.
13 Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb;75(2):281-95.